Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

(OP:SDZNY)

85.28 +0.81 (+0.96%)

Streaming Delayed Price Updated: 3:52 PM EST, Mar 4, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	55,375
Open	84.94
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	84.47
Today's Range	84.46 - 85.34
52wk Range	35.61 - 94.15
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive

March 03, 2026

As of March 3, 2026, Viatris Inc. (NASDAQ: VTRS) stands at a pivotal crossroads in its corporate evolution. Formed less than six years ago through one of the most complex healthcare mergers in recent...

Via Finterra

Stability Meets Scale: Why Johnson & Johnson is Poised for a Breakout 2026

January 23, 2026

As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its...

Via MarketMinute

Performance

YTD	+16.8%	+16.8%
1 Month	+8.2%	+8.2%
3 Month	+18.9%	+18.9%
6 Month	+38.1%	+38.1%
1 Year	+91.3%	+91.3%

More News

Sandoz launches affordable iron sucrose injection for treatment of iron deficiency anemia in patients with chronic kidney disease in US

September 24, 2025

From Sandoz

Via Business Wire

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations

August 12, 2025

From Sandoz Group

Via GlobeNewswire

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter

August 07, 2025

From Sandoz Group

Via GlobeNewswire

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

July 30, 2025

From Sandoz Group

Via GlobeNewswire

Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach

July 01, 2025

From Sandoz Group

Via GlobeNewswire

Ozempic Patent Expires In Canada After Novo Nordisk Fails To Pay $450 Fee: 'It's The Second-Largest Semaglutide Market In The World,' Says Sandoz CEO Richard Saynor ↗

June 16, 2025

Via Benzinga

Life Sciences Investor Forum: Now Available for Online Viewing

June 13, 2025

From Virtual Investor Conferences

Via GlobeNewswire

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]

June 02, 2025

From Sandoz Group

Via GlobeNewswire

Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars

May 21, 2025

From Sandoz Group

Via GlobeNewswire

Life Sciences Investor Forum Agenda Announced for June 11th-12th

June 10, 2025

From Virtual Investor Conferences

Via GlobeNewswire

Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed

April 30, 2025

From Sandoz Group

Via GlobeNewswire

Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications

April 29, 2025

From Sandoz Group

Via GlobeNewswire

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

April 15, 2025

From Sandoz Group

Via GlobeNewswire

Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug ↗

April 14, 2025

Via Benzinga

[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

April 14, 2025

From Sandoz Group

Via GlobeNewswire

Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

April 14, 2025

From Sandoz Group

Via GlobeNewswire

Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility

March 31, 2025

From Sandoz Group

Via GlobeNewswire

Sandoz reports strong FY 2024 results and Q4 2024 sales

March 05, 2025

From Sandoz Group

Via GlobeNewswire

NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects ↗

February 24, 2025

Via Benzinga

Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]

February 24, 2025

From Sandoz Group

Via GlobeNewswire

Francisco Ballester to retire; Peter Stenico appointed President Region International

February 03, 2025

From Sandoz Group

Via GlobeNewswire

Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference

January 14, 2025

From Sandoz Group

Via GlobeNewswire

Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation

December 17, 2024

From Sandoz Group

Via GlobeNewswire

Frequently Asked Questions

Is SDZNY publicly traded?

Yes, SDZNY is publicly traded.

What exchange does SDZNY trade on?

SDZNY trades on the OTC Traded

What is the ticker symbol for SDZNY?

The ticker symbol for SDZNY is SDZNY on the OTC Traded

What is the current price of SDZNY?

The current price of SDZNY is 85.28

When was SDZNY last traded?

The last trade of SDZNY was at 03/04/26 03:52 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.